Real time RT-PCR validation of microarray data. Nine genes were randomly selected for real time RT-PCR. Two of these genes (adipsin and vimentin) were identified as being significantly regulated in both the cell lines and in de novo AML patients. The "fold-change" (Log2) of the RNA transcripts was calculated in the patient who responded to tipifarnib (patient A) by using the treated (day 15) versus the matched baseline sample for both PCR and microarray data. Linear regression analysis was performed and the coefficient of variation was calculated. Italicized genes were identified as being significantly regulated by tipifarnib in both AML cell lines and patient samples. Error bars are standard deviations.